Oncologists are excited about CAR-T therapy in 2025 because the technology has crossed a critical threshold — moving from a last-resort experimental treatment for blood cancers into a broader platform showing real results against solid tumors, autoimmune diseases, and previously untreatable malignancies. With seven FDA-approved CAR-T products now available in the United States and clinical trial data from ASCO 2025 showing tumor shrinkage in 85 percent of evaluable glioblastoma patients treated with a bivalent CAR-T approach, the field has entered a phase that even cautious researchers are calling transformative. For readers of this site who follow brain health and neurological conditions closely, glioblastoma breakthroughs deserve particular attention. Glioblastoma remains one of the most lethal brain cancers, with median survival still measured in months for recurrent cases.
The fact that CAR-T cells are now demonstrating measurable tumor reduction in this disease — not just in a petri dish but in real patients — represents a genuine shift. This article covers the FDA milestones driving optimism, the solid tumor data that changed the conversation at ASCO 2025, the surprising expansion into autoimmune disease, and the cost and safety realities that temper the enthusiasm with necessary caution. Beyond oncology, CAR-T research published in the New England Journal of Medicine in 2025 introduced in vivo CAR-T generation for lupus — creating the engineered cells directly inside the patient’s body. That kind of innovation suggests the platform’s potential extends well beyond cancer, with possible implications for neuroinflammatory and autoimmune conditions affecting the brain.
Table of Contents
- What FDA Approvals Are Fueling Oncologist Excitement About CAR-T in 2025?
- How Is CAR-T Breaking Into Solid Tumors — and What Are the Limitations?
- What Does CAR-T for Autoimmune Disease Mean for Brain Health?
- How Much Does CAR-T Cost, and Who Can Actually Access It?
- What About the Cancer Risk From CAR-T Itself?
- What Does the FDA’s New Superiority Standard Mean for Future CAR-T Approvals?
- Where Is CAR-T Headed Beyond 2025?
- Conclusion
- Frequently Asked Questions
What FDA Approvals Are Fueling Oncologist Excitement About CAR-T in 2025?
The regulatory landscape for CAR-T therapy shifted significantly over the past year. In December 2025, the FDA approved lisocabtagene maraleucel (Breyanzi) for relapsed or refractory marginal zone lymphoma after two or more prior therapies — adding yet another indication to an already expanding list. Around the same time, axicabtagene ciloleucel (Yescarta) received a label expansion to include primary CNS lymphoma, a brain cancer that has historically been difficult to treat and carries particular relevance for anyone tracking neurological malignancies. These approvals reflect a pattern: CAR-T is no longer narrowly confined to a handful of aggressive blood cancers. Perhaps more telling than individual approvals is the FDA’s decision to eliminate Risk Evaluation and Mitigation Strategy (REMS) programs for all approved CAR-T therapies. REMS programs had required specialized certification for treatment centers and imposed strict monitoring protocols.
The removal signals that real-world safety data has convinced regulators that CAR-T side effects — primarily cytokine release syndrome and neurotoxicity — are predictable and manageable within roughly two weeks of infusion. For community oncologists who previously viewed CAR-T as something only major academic centers could handle, this is a practical barrier coming down. In January 2026, the FDA granted breakthrough therapy designation to Wugen’s WU-CART-007 for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma. This matters because T-cell malignancies have been a blind spot for CAR-T. Traditional CAR-T products target markers on B cells, which means turning them against T-cell cancers risks destroying the very immune cells needed to fight the disease. A breakthrough designation for a T-cell malignancy CAR-T product suggests viable engineering solutions are finally emerging for this challenge.
How Is CAR-T Breaking Into Solid Tumors — and What Are the Limitations?
The most dramatic data presented at ASCO 2025 came from glioblastoma trials. Bivalent CAR-T cells engineered to target both EGFR epitope 806 and IL13Rα2 achieved tumor shrinkage in 85 percent of evaluable patients across a cohort of 18 treated individuals, with a median tumor reduction of 35 percent. Separately, the INCIPIENT trial tested CARv3-TEAM-E T cells — which target EGFRvIII while also secreting an anti-EGFR antibody — and achieved stable disease in five of seven patients with recurrent glioblastoma. For a cancer where “stable disease” itself represents a meaningful outcome, these numbers generated genuine enthusiasm among neuro-oncologists. However, solid tumor results demand careful interpretation. Twelve phase I clinical studies for solid tumors were presented at ASCO 2025, spanning brain, gastric, liver, sarcoma, and neuroblastoma cancers, but phase I trials are designed primarily to assess safety and dosing — not to prove efficacy.
Response rates in early-phase solid tumor trials often do not hold up in larger studies. The tumor microenvironment in solid cancers creates physical and immunological barriers that blood cancers do not, including suppressive immune cells, poor T-cell infiltration, and antigen heterogeneity that allows tumors to evade CAR-T targeting. If a tumor can downregulate the antigen the CAR-T cells are engineered to attack, the therapy may stop working. One encouraging data point came from outside the brain. ALLO-316, an allogeneic (off-the-shelf) CAR-T targeting CD70 in renal cell carcinoma, achieved a 20 percent objective response rate overall and 33 percent in tumors with high CD70 expression, with grade 3 or higher cytokine release syndrome occurring in only 2 percent of patients. The low toxicity profile is noteworthy because it suggests that allogeneic CAR-T products — made from donor cells rather than the patient’s own — may offer a viable path toward treating solid tumors without the severe side effects that have plagued some autologous approaches.
What Does CAR-T for Autoimmune Disease Mean for Brain Health?
One of the most unexpected developments in CAR-T therapy has been its expansion into autoimmune disease — a shift with direct implications for neuroinflammatory conditions. At the American College of Rheumatology’s Convergence 2025 meeting, researchers presented data on CTA313, a dual-targeted CAR-T therapy hitting both CD19 and BCMA, in patients with refractory systemic lupus erythematosus. All five evaluable patients achieved SRI-4 response, and three reached drug-free remission, meaning they discontinued all immunosuppressive medications. Side effects were limited to Grade 1 cytokine release syndrome with no neurotoxicity observed. Bristol Myers Squibb’s Breakfree-1 trial broadened the autoimmune picture further.
Across 71 patients with lupus, systemic sclerosis, and inflammatory myopathies, 94 percent of evaluable patients remained off chronic immunosuppressive therapy, with lupus responses sustained up to 18 months. The implications for neurological autoimmune conditions — multiple sclerosis, neuromyelitis optica, autoimmune encephalitis — are being actively explored by research groups, though clinical data in those specific indications remains early. Perhaps most striking was a study published in the New England Journal of Medicine in 2025 demonstrating in vivo CAR-T generation for lupus. Rather than extracting a patient’s T cells, engineering them in a laboratory over weeks, and reinfusing them, this approach uses a viral vector to reprogram T cells directly inside the patient’s body. If this technique proves safe and scalable, it could fundamentally alter the cost and accessibility equation — not just for autoimmune disease but potentially for any condition where immune cells need to be redirected, including certain neuroinflammatory disorders.
How Much Does CAR-T Cost, and Who Can Actually Access It?
The financial reality of CAR-T therapy remains its most significant barrier. Treatment costs in the United States range from $373,000 to $475,000 per infusion, and that figure covers only the therapy itself — not the hospitalization, monitoring, or management of side effects that surround it. BCMA-targeted therapies for multiple myeloma, such as Abecma and Carvykti, sit at the high end, exceeding $450,000 to $465,000 per treatment. The global CAR-T therapy market was valued at approximately $5.1 to $6.0 billion in 2025, with projections reaching as high as $23 to $128 billion by 2034, depending on the analyst and the assumptions about new indications and market access.
The tradeoff patients and oncologists face is stark. For someone with relapsed or refractory large B-cell lymphoma who has failed multiple lines of chemotherapy, a one-time CAR-T infusion that offers a chance of durable remission may represent better value than years of ongoing treatment with conventional agents. But the upfront cost means access depends heavily on insurance coverage, geography, and institutional capacity. Allogeneic (off-the-shelf) CAR-T products and in vivo approaches could eventually reduce costs by eliminating the individualized manufacturing process, which currently takes two to four weeks per patient. Until those alternatives mature, the gap between CAR-T’s medical promise and its practical accessibility will remain a defining tension in the field.
What About the Cancer Risk From CAR-T Itself?
In January 2024, the FDA added boxed warnings to all approved CAR-T products regarding the risk of T-cell malignancies developing after treatment. The warnings were prompted by case reports of patients developing T-cell lymphomas — sometimes harboring the CAR transgene itself — months or years after CAR-T infusion. The news generated significant anxiety among patients and clinicians alike, and it remains a legitimate concern that requires lifelong monitoring. However, the data that has accumulated since those warnings paints a more measured picture. A meta-analysis of 5,517 patients across 25 studies found an overall secondary malignancy rate of 5.8 percent, with only five cases of T-cell cancers — an incidence of 0.09 percent.
A Stanford study following more than 700 patients found a secondary cancer risk of approximately 6.5 percent within three years of treatment. Oncologists generally consider this rate low relative to the benefit, particularly given that the patients receiving CAR-T have already undergone multiple rounds of chemotherapy, which itself carries substantial secondary cancer risk. The important caveat is that follow-up periods remain relatively short, and longer-term surveillance may reveal risks not yet apparent. For patients and families weighing CAR-T against other options, the honest framing is this: the therapy carries a small but real risk of secondary malignancy that must be monitored indefinitely, but for patients whose cancers have resisted everything else, the alternative is often progression and death. The risk-benefit calculus, while not simple, generally favors treatment in the populations currently approved for CAR-T.
What Does the FDA’s New Superiority Standard Mean for Future CAR-T Approvals?
In December 2025, the FDA outlined a new standard for future CAR-T approvals that signals a major shift in how the agency views the therapy. Going forward, the FDA will require randomized trials with standard-of-care controls and clear evidence of superiority over existing therapies. Earlier CAR-T approvals often relied on single-arm studies showing high response rates in patients who had no other options — a reasonable approach for a novel therapy in heavily pretreated populations but not sufficient as the field matures.
This regulatory evolution cuts both ways. On one hand, it raises the bar for new entrants, potentially slowing the pace of approvals and increasing development costs. On the other hand, it signals that the FDA now views CAR-T as an established treatment modality rather than an experimental one — a vote of institutional confidence. For patients, randomized trials will eventually generate the comparative data needed to determine where CAR-T fits in treatment sequences and whether earlier use produces better outcomes than reserving it as a later-line option.
Where Is CAR-T Headed Beyond 2025?
The trajectory of CAR-T therapy points toward several convergences that could reshape treatment across oncology, autoimmunity, and potentially neurology. Allogeneic and in vivo CAR-T approaches aim to solve the manufacturing bottleneck and cost problem simultaneously. Solid tumor programs, while still early, are accumulating the kind of data that attracts larger investment and broader clinical trials.
The expansion into autoimmune disease opens a pathway toward conditions affecting the central nervous system, where dysregulated immune responses drive diseases like multiple sclerosis and autoimmune encephalitis. For those following brain health specifically, the glioblastoma data from ASCO 2025 and the FDA’s expansion of Yescarta into primary CNS lymphoma represent concrete steps toward addressing cancers that have resisted decades of conventional approaches. The next few years will determine whether early-phase promise translates into durable, reproducible benefit — but the reasons for cautious optimism are grounded in data rather than speculation.
Conclusion
CAR-T therapy in 2025 earned oncologist enthusiasm through tangible progress: seven FDA-approved products, the removal of REMS monitoring requirements, meaningful response rates in glioblastoma and other solid tumors, and striking results in autoimmune diseases that hint at a broader immunological platform. The FDA’s new superiority standard for future approvals reflects the field’s graduation from experimental curiosity to established treatment category. For brain health, the CNS lymphoma label expansion and glioblastoma trial results carry particular weight.
The challenges remain substantial — costs exceeding $400,000 per infusion, a small but real secondary cancer risk requiring lifelong monitoring, and solid tumor results that are still in early phases. But for patients with cancers or autoimmune conditions that have exhausted conventional options, CAR-T represents something rare in medicine: a genuinely new mechanism of action producing outcomes that older approaches cannot match. The question is no longer whether CAR-T works, but how far its reach can extend.
Frequently Asked Questions
What is CAR-T therapy and how does it work?
CAR-T (chimeric antigen receptor T-cell) therapy involves extracting a patient’s T cells, genetically engineering them to recognize and attack specific proteins on cancer cells, then infusing them back into the patient. Newer in vivo approaches aim to perform this engineering directly inside the body.
How many FDA-approved CAR-T therapies are available in 2025?
Seven CAR-T therapies are FDA-approved in the United States as of 2025, targeting cancers including acute lymphoblastic leukemia, large B-cell lymphoma, marginal zone lymphoma, primary CNS lymphoma, and multiple myeloma.
Can CAR-T therapy treat brain cancer?
Clinical trials presented at ASCO 2025 showed promising early results in glioblastoma, with one bivalent CAR-T approach achieving tumor shrinkage in 85 percent of evaluable patients. The FDA also expanded Yescarta’s label to include primary CNS lymphoma. These are early-phase results and broader trials are needed.
What are the main side effects of CAR-T therapy?
The primary side effects are cytokine release syndrome (an inflammatory response that can range from mild fever to organ dysfunction) and neurotoxicity. The FDA’s removal of REMS programs in 2025 reflected growing confidence that these side effects are predictable and manageable within approximately two weeks of infusion.
How much does CAR-T therapy cost?
In the United States, CAR-T therapy costs between $373,000 and $475,000 per infusion, not including hospitalization and supportive care. BCMA-targeted therapies for multiple myeloma can exceed $465,000.
Is there a risk of developing cancer from CAR-T treatment?
A meta-analysis of over 5,500 patients found a secondary malignancy rate of 5.8 percent overall, with T-cell cancers occurring in only 0.09 percent of cases. The FDA requires boxed warnings and lifelong monitoring, but oncologists generally consider the risk low relative to the therapeutic benefit for patients with refractory cancers.
